Our study focused on the development of vaccines that contain phosphorylation patterns which are considered to be AD specific to reduce possible adverse effects, like axonal damage and gliosis or the occurrence of tau autoantibodies, as reported by others [13,26,58]. This evidence concerns the gene MAPT and Alzheimer disease.